2nd Jun 2009 12:50
2/06/2009
For immediate release
AIM/PLUS: RGT
ReGen Signs Exclusive Distribution Agreement for Colostrinin™ in Poland
ReGen Therapeutics Plc ('ReGen' or the 'Company') announces that it has today signed an agreement with Tagerr Polska* for the exclusive distribution and marketing of its nutritional supplement Colostrinin™ in Poland. This comes after a period of test - marketing by Tagerr during which Tagerr also satisfied all necessary regulatory requirements to import/distribute the product in Poland. To date Colostrinin™ is marketed in the US, Canada and Australia under the brand name CogniSure™ ** and in Cyprus under the brand name Cognase™ *** as a nutritional supplement to 'support healthy brain ageing and cognition in humans'.
Commenting on this agreement Percy Lomax, Chairman and Chief Executive Officer of ReGen said :
'Poland is the country where Colostrinin™ was first discovered and we know from various communications that there is significant knowledge of the product in Poland. Poland has a population of 38 million people and a Gross Domestic Product per Capita of $11,072. As such both Tagerr Polska and ourselves are optimistic that the volume of sales here should be significant.'
\* Tagerr Polska is an affliate of Tagerr a professional services and trading company established in Köln, Germany. In operation since 1995, Tagerr has enjoyed considerable successes in marketing and distributing consumer products, including food supplements, in central Europe and Germany. (www.cognisure.eu)
**Colostrinin™ for use as a human nutraceutical is licensed in North America and Australasia to Metagenics Inc. of San Clemente, California (www.metagenics.com).
*** Colostrinin™ is distributed in the Republic of Cyprus by Golgi Pharmaceuticals Ltd (www.healthybrainaging.com)
For further information:
Percy Lomax ReGen Therapeutics Plc Tel No 020 7153 4920
Roland Cornish/Felicity Geidt Beaumont Cornish Limited Tel No 020 7628 3396
Nick Bealer/David Scott Alexander David Tel No 020 7448 9820
Notes to Editors:
Colostrinin™ is derived from colostrum a mammal's first milk after birth and is produced in a production line in S Dakota, freeze dried in Oregon and tabletted at Metagenics Inc plant in California. Metagenics are the distributors in North America and Australia. If full production and sales were achieved on North American margins revenue to the Company would be $10 million before relatively low head office expenses. It would be possible, by spending around another $550,000 to bring production facilities up to a level to generate revenue of around $50 million.
Colostrinin™ has been available in the professional channel of the healthcare market in North America and Australia for over a year. Although achieving professional awareness and endorsement was a necessary first step, retail distribution, was always and remains our objective.
Related Shares:
TILS.L